DalsnaFinance Account

Pfizer $PFE

Health Care · Pharmaceuticals · NYSE/NASDAQ

S&P 500 Russell 1000 New York

Create a scorecard

$30.14

+0.69 (+2.36%)

As of Oct 20, 2026, 12:08 PM EDT

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Jun 14, 2026, the first target we tracked for PFE.

Key facts

52-week range (closes): $23.67 – $29.02 Lowest close Jun 25, 2026, highest Sep 2, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Fiscal year ends: December Fiscal 2025 ended Dec 31, 2025, from SEC filings
In the S&P 500 since: Mar 4, 1957 · All S&P 500 changes
Analyst coverage: 7 open price targets from 7 firms: Bank of America, BMO Capital Markets, Cantor Fitzgerald, HSBC, JPMorgan, RBC Capital Markets, Scotiabank Approved targets tracked here; see the analyst section below

Pfizer (PFE) is trading up at $30.14 (+2.36%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on PFE

Current price targets from 7 firms average $29, median $29, ranging from $25 to $33 — the average is 4% below the current $30.1. Each is tracked to its date and scored the same way a member's call is.

Cantor Fitzgerald $28.3 → $28 by Oct 2027 Neutral Oct 10, 2026 via TIKR.com · Cantor Fitzgerald's track record
Bank of America $28.3 → $29 by Oct 2027 Neutral Oct 10, 2026 via TIKR.com · Bank of America's track record
JPMorgan $28.3 → $30 by Oct 2027 Neutral Oct 10, 2026 via The Globe and Mail · JPMorgan's track record
Scotiabank $27.5 → $33 by Oct 2027 Sector Outperform Oct 6, 2026 via GuruFocus · Scotiabank's track record
BMO Capital Markets $27.3 → $30 by Aug 2027 Buy Aug 18, 2026 via 富途牛牛 · BMO Capital Markets's track record
HSBC $23.7 → $28 by Jul 2027 Hold Jul 6, 2026 via Investing.com · HSBC's track record
RBC Capital Markets $26 → $25 by Jun 2027 Sector Perform Jun 14, 2026 via finance.yahoo.com · RBC Capital Markets's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Pfizer revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Pfizer annual financial statements
	FY2016Dec 2016	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$52.8B	$52.5B	$40.8B	$40.9B	$41.7B	$81.3B	$101.2B	$59.6B	$63.6B	$62.6B
Growth (year over year)	+8.1%	−0.5%	−22.3%	+0.2%	+1.8%	+95.2%	+24.5%	−41.1%	+6.8%	−1.6%
Gross profit	$40.5B	$41.3B	$31.8B	$32.9B	$33.2B	$50.5B	$66.8B	$34.6B	$45.8B	$46.5B
Gross margin	76.7%	78.6%	78.0%	80.3%	79.6%	62.1%	66.1%	58.1%	71.9%	74.3%
Net income	$7.21B	$21.3B	$11.2B	$16.0B	$9.16B	$22.0B	$31.4B	$2.12B	$8.03B	$7.77B
Net margin	13.7%	40.6%	27.3%	39.2%	22.0%	27.0%	31.0%	3.6%	12.6%	12.4%
EPS (diluted)	$0.78	$2.35	$1.25	$2.82	$1.63	$3.85	$5.47	$0.37	$1.41	$1.36
Balance sheet
Cash and equivalents	$2.60B	$1.34B	$1.14B	$1.12B	$1.79B	$1.94B	$416.0M	$2.85B	$1.04B	$1.14B
Total assets	$171.6B	$171.8B	$159.4B	$167.6B	$154.2B	$181.5B	$197.2B	$226.5B	$213.4B	$208.2B
Total liabilities	$111.8B	$100.1B	$95.7B	$104.1B	$90.8B	$104.0B	$101.3B	$137.2B	$124.9B	$121.4B
Long-term debt	$31.4B	$33.5B	$32.9B	$36.0B	$37.1B	$36.2B	$32.9B	$61.5B	$57.4B	$61.6B
Shareholders' equity	$59.5B	$71.3B	$63.4B	$63.1B	$63.2B	$77.2B	$95.7B	$89.0B	$88.2B	$86.5B
Cash flow
Operating cash flow	$16.2B	$16.8B	$15.8B	$12.6B	$14.4B	$32.6B	$29.3B	$8.70B	$12.7B	$11.7B
Capital expenditure	$1.82B	$1.96B	$1.98B	$2.05B	$2.23B	$2.71B	$3.24B	$3.91B	$2.91B	$2.63B
Free cash flow	$14.4B	$14.8B	$13.8B	$10.5B	$12.2B	$29.9B	$26.0B	$4.79B	$9.84B	$9.07B
Share buybacks	$5.00B	$5.00B	$12.2B	$8.87B	$0	$0	$2.00B	$0	$0	—

RevenueNet incomeNet margin (right axis, %)

Pfizer quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$17.7B	$17.8B	$13.7B	$14.7B	$16.7B	$17.6B	$14.5B	$15.0B
Growth (year over year)	+31.2%	+21.9%	−7.8%	+10.3%	−5.9%	−1.2%	+5.4%	+2.6%
Gross profit	$12.4B	$11.9B	$10.9B	$10.9B	$12.5B	$12.3B	$10.9B	$10.9B
Gross margin	70.3%	66.7%	79.3%	74.2%	74.9%	70.0%	75.4%	72.8%
Net income	$4.46B	$410.0M	$2.97B	$2.91B	$3.54B	−$1.65B	$2.69B	−$248.0M
Net margin	25.2%	2.3%	21.6%	19.9%	21.3%	−9.4%	18.6%	−1.6%
EPS (diluted)	$0.78	$0.07	$0.52	$0.51	$0.62	−$0.29	$0.47	−$0.04
Balance sheet
Cash and equivalents	$1.09B	$1.04B	$1.43B	$1.64B	$1.34B	$1.14B	$1.70B	$976.0M
Total assets	$219.5B	$213.4B	$208.0B	$206.1B	$208.7B	$208.2B	$207.6B	$201.1B
Total liabilities	$126.9B	$124.9B	$117.4B	$117.1B	$115.6B	$121.4B	$117.2B	$115.6B
Long-term debt	$58.0B	$57.4B	$57.6B	$57.5B	$57.4B	$61.6B	$60.6B	$60.5B
Shareholders' equity	$92.3B	$88.2B	$90.3B	$88.7B	$92.8B	$86.5B	$90.1B	$85.2B
Cash flow
Operating cash flow	$6.71B	$6.72B	$2.33B	−$582.0M	$4.60B	$5.35B	$2.62B	$835.0M
Capital expenditure	$651.0M	$917.0M	$564.0M	$618.0M	$602.0M	$845.0M	$436.0M	$533.0M
Free cash flow	$6.06B	$5.80B	$1.77B	−$1.20B	$4.00B	$4.50B	$2.18B	$302.0M

From Pfizer's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Pfizer vs the Health Care sector and the S&P 500

Pfizer's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Pfizer compared with the median Health Care company and the median S&P 500 company
Measure	Pfizer	Health Care (59 other S&P 500 companies)	S&P 500 (502 other companies)
Revenue growth, latest fiscal year	−1.6%	+7.2%	+7.0%
Net margin, latest fiscal year	12.4%	13.1%	13.0%
Dividend per share, latest fiscal year	$1.72	$2.48	$2.40
Share price change, 1 year	+19.2%	+19.8%	+5.6%

Pfizer: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Pfizer included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.

About Pfizer

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer and Charles F. Erhart, Pfizer is one of the oldest pharmaceutical companies in North America.

Source: Wikipedia — Pfizer